Compound tirzepatide side effects: separating real risk from TikTok panic

What's this video probably claiming?

Based on the caption "I made a horrible decision" paired with hashtags for tirzepatide, compound, and GLP-1, this creator almost certainly had a rough experience with compounded tirzepatide and is framing it as a cautionary tale. The "sick" hashtag suggests she experienced significant side effects, nausea, vomiting, fatigue, or possibly a more serious adverse event. Videos in this genre typically follow a pattern: person starts compounded GLP-1, takes too much too fast, feels terrible, and concludes the drug itself (or the compounding source) was a mistake. Sometimes the creator implies the compound formulation was the problem. Sometimes they're describing a completely predictable dose-escalation response that would have happened with brand-name Zepbound too. The distinction matters enormously, and most TikTok storytelling glosses right over it.

What does the science actually show?

Tirzepatide's side effect profile is well-documented from the SURMOUNT trial series. In SURMOUNT-1 (Jastreboff et al., 2022, NEJM), gastrointestinal adverse events affected roughly 44% of participants at the 15mg dose, with nausea being the most common complaint at around 31%. Most events were rated mild to moderate and were concentrated during dose-escalation phases. The drug works on both GIP and GLP-1 receptors simultaneously, which is part of why it produces stronger weight loss than semaglutide in head-to-head data (SURMOUNT-5, Wadden et al., 2025), but also why GI side effects can be pronounced early on. Crucially, the phase III data used participants on a standardized titration schedule with brand-name drug. Compounded tirzepatide has no equivalent clinical trial data supporting its safety or efficacy, and the FDA has specifically flagged compounded versions as presenting unique risks, including dosing errors from reconstituted powder formulations.

Where does the social media noise diverge from clinical reality?

Here is where things get genuinely complicated. A lot of the "I got sick on compound" content on TikTok conflates two separate problems. First, there is the predictable pharmacological response: GLP-1-based drugs slow gastric emptying and suppress appetite hard, and people who self-start at doses higher than recommended, or skip titration, will feel awful. That is not a compounding problem, that is basic pharmacology. Second, there is a real and separate concern about quality control in compounded tirzepatide. The FDA issued warnings in 2024 about dosing errors with compounded tirzepatide salts versus the base form used in Zepbound. These are not the same compound, and the FDA has been explicit that compounded versions are not FDA-approved and not shown to be safe or effective. Treating a personal bad experience as evidence that the drug category is dangerous, without distinguishing between formulation issues and user error or expected side effects, produces genuinely misleading health content.

What should you actually know?

Side effects from tirzepatide, including compounded versions, are real and common early in treatment. They are also largely manageable with proper titration and medical supervision. The clinical trial data shows that discontinuation rates due to adverse events in SURMOUNT-1 were around 4.3% at 15mg, meaning the vast majority of people tolerate the drug with appropriate dose escalation. If you are sourcing compounded tirzepatide without a licensed prescriber reviewing your health history and titration plan, you are taking on additional risk that has nothing to do with how the drug works and everything to do with oversight. FormBlends only provides GLP-1 medications through licensed providers who conduct medical evaluations and supervise dose escalation. A dramatic TikTok should not be your primary data point for a decision about a prescription medication, in either direction.